Kfir Ben-David, M.D., FACS, Joins The Eugene M. and Christine E. Lynn Cancer Institute as a Surgical Oncologist - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Kfir Ben-David, M.D., FACS, Joins The Eugene M. and Christine E. Lynn Cancer Institute as a Surgical Oncologist

Fellowship-trained surgical oncologist Kfir Ben-David, M.D., FACS, has joined the Eugene M. and Christine E. Lynn Cancer Institute, part of Baptist Health, at Boca Raton Regional Hospital.

  • By

  • September 23, 2026

  • 3 min

Share

Clinical Scorecard: Kfir Ben-David, M.D., FACS, Joins The Eugene M. and Christine E. Lynn Cancer Institute as a Surgical Oncologist

At a Glance

CategoryDetail
ConditionGastrointestinal Cancer
Key MechanismsMinimally invasive surgical techniques and robotic surgery
Target PopulationPatients with esophageal, gastric, and pancreatic cancers
Care SettingMultidisciplinary cancer care team

Key Highlights

  • Specializes in complex minimally invasive gastrointestinal surgery
  • Expertise in esophageal cancer, gastric cancer, and pancreatic cancer
  • Chair of the Department of Surgery at Florida Atlantic University
  • Over 100 peer-reviewed publications
  • Patient-centered approach emphasizing compassion and shared decision-making

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients undergoing surgical treatment for gastrointestinal cancers

          Focus on robotic esophagectomy and robotic Whipple procedures

          Clinical Best Practices

          • Individualized care reflecting patient circumstances and goals
          • High priority on transparency and support throughout the cancer journey

          Related Resources & Content

            Original Source(s)

            Kfir Ben-David, M.D., FACS, Joins The Eugene M. and Christine E. Lynn Cancer Institute as a Surgical Oncologist

            • by

            • September 23, 2026

            Related Content

            Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

            All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

            • September 16, 2026

            • 2 min
            Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027

            U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.

            • by

            • September 15, 2026

            • 3 min
            Intraoperative Evaluation of Sarcoma Surgical Margins With Indocyanine Green Fluorescence Imaging: Results From an Observational Study